Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts
Abstract: Measurable residual disease (MRD) is a powerful predictor of clinical outcomes in acute lymphoblastic leukemia (ALL). In addition to its clear prognostic importance, MRD information is increasingly used in clinical decision algorithms to guide therapeutic interventions. Although it is well...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952925000503 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850218596579409920 |
|---|---|
| author | Nicholas J. Short Ibrahim Aldoss Daniel J. DeAngelo Marina Konopleva Jessica Leonard Aaron C. Logan Jae Park Bijal Shah Wendy Stock Elias Jabbour |
| author_facet | Nicholas J. Short Ibrahim Aldoss Daniel J. DeAngelo Marina Konopleva Jessica Leonard Aaron C. Logan Jae Park Bijal Shah Wendy Stock Elias Jabbour |
| author_sort | Nicholas J. Short |
| collection | DOAJ |
| description | Abstract: Measurable residual disease (MRD) is a powerful predictor of clinical outcomes in acute lymphoblastic leukemia (ALL). In addition to its clear prognostic importance, MRD information is increasingly used in clinical decision algorithms to guide therapeutic interventions. Although it is well established that achievement of MRD-negative remission is an important end point of ALL therapy, the prognostic and therapeutic implications of MRD in an individual patient are influenced by both disease-related factors (eg, cytomolecular risk) and assay-related factors (eg, sensitivity, specimen source, and timing of assessment), which add complexity to MRD-guided treatment decisions. In this review, we discuss the data supporting the use of MRD assessment in adult ALL and how this information can rationally inform clinical decisions, including selection of patients for MRD-directed therapies or allogeneic hematopoietic stem cell transplantation. We also discuss important interpretative challenges related to novel high sensitivity next-generation sequencing–based MRD assays, which are becoming increasingly used in clinical practice. |
| format | Article |
| id | doaj-art-ecf74abc984c41dd915502e3f53f7ecb |
| institution | OA Journals |
| issn | 2473-9529 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Blood Advances |
| spelling | doaj-art-ecf74abc984c41dd915502e3f53f7ecb2025-08-20T02:07:40ZengElsevierBlood Advances2473-95292025-03-01961442145110.1182/bloodadvances.2024015441Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US expertsNicholas J. Short0Ibrahim Aldoss1Daniel J. DeAngelo2Marina Konopleva3Jessica Leonard4Aaron C. Logan5Jae Park6Bijal Shah7Wendy Stock8Elias Jabbour9Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; Correspondence: Nicholas J. Short, Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030;Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CADepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MADepartment of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NYDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, ORDivision of Hematology, Blood and Marrow Transplantation, and Cellular Therapy, Department of Medicine, University of California San Francisco, San Francisco, CAMemorial Sloan Kettering Cancer Center, New York, NYDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FLDepartment of Medicine Section of Hematology-Oncology, University of Chicago, Chicago, ILDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TXAbstract: Measurable residual disease (MRD) is a powerful predictor of clinical outcomes in acute lymphoblastic leukemia (ALL). In addition to its clear prognostic importance, MRD information is increasingly used in clinical decision algorithms to guide therapeutic interventions. Although it is well established that achievement of MRD-negative remission is an important end point of ALL therapy, the prognostic and therapeutic implications of MRD in an individual patient are influenced by both disease-related factors (eg, cytomolecular risk) and assay-related factors (eg, sensitivity, specimen source, and timing of assessment), which add complexity to MRD-guided treatment decisions. In this review, we discuss the data supporting the use of MRD assessment in adult ALL and how this information can rationally inform clinical decisions, including selection of patients for MRD-directed therapies or allogeneic hematopoietic stem cell transplantation. We also discuss important interpretative challenges related to novel high sensitivity next-generation sequencing–based MRD assays, which are becoming increasingly used in clinical practice.http://www.sciencedirect.com/science/article/pii/S2473952925000503 |
| spellingShingle | Nicholas J. Short Ibrahim Aldoss Daniel J. DeAngelo Marina Konopleva Jessica Leonard Aaron C. Logan Jae Park Bijal Shah Wendy Stock Elias Jabbour Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts Blood Advances |
| title | Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts |
| title_full | Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts |
| title_fullStr | Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts |
| title_full_unstemmed | Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts |
| title_short | Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts |
| title_sort | clinical use of measurable residual disease in adult all recommendations from a panel of us experts |
| url | http://www.sciencedirect.com/science/article/pii/S2473952925000503 |
| work_keys_str_mv | AT nicholasjshort clinicaluseofmeasurableresidualdiseaseinadultallrecommendationsfromapanelofusexperts AT ibrahimaldoss clinicaluseofmeasurableresidualdiseaseinadultallrecommendationsfromapanelofusexperts AT danieljdeangelo clinicaluseofmeasurableresidualdiseaseinadultallrecommendationsfromapanelofusexperts AT marinakonopleva clinicaluseofmeasurableresidualdiseaseinadultallrecommendationsfromapanelofusexperts AT jessicaleonard clinicaluseofmeasurableresidualdiseaseinadultallrecommendationsfromapanelofusexperts AT aaronclogan clinicaluseofmeasurableresidualdiseaseinadultallrecommendationsfromapanelofusexperts AT jaepark clinicaluseofmeasurableresidualdiseaseinadultallrecommendationsfromapanelofusexperts AT bijalshah clinicaluseofmeasurableresidualdiseaseinadultallrecommendationsfromapanelofusexperts AT wendystock clinicaluseofmeasurableresidualdiseaseinadultallrecommendationsfromapanelofusexperts AT eliasjabbour clinicaluseofmeasurableresidualdiseaseinadultallrecommendationsfromapanelofusexperts |